Some patients treated with a bimatoprost slow-release implant over 1 year can maintain the IOP-lowering effect without relapse for 2 years or even 4 years after the last administration, according to a study.
“We believe that upregulation of the metalloproteinases and other extracellular matrix proteins produced by high bimatoprost concentrations in target tissues may lead to sustained tissue remodeling and long-term IOP reduction in the absence of drug,” Felipe A. Medeiros, MD, PhD, said at the virtual Association for Research in Vision and Ophthalmology meeting.
Durysta